(409) A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Painful Diabetic Peripheral Neuropathy ◽

A multinational, randomized, double-blind, placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime in Type 2 or non-ambulatory Type 3 spinal muscular atrophy

Neuromuscular Disorders ◽

10.1016/s0960-8966(17)30304-8 ◽

2017 ◽

Vol 27 ◽

pp. S29

Author(s):

J. Buchbjerg ◽

E. Bertini ◽

E. Dessaud ◽

E. Mercuri ◽

F. Muntoni ◽

...

Keyword(s):

Spinal Muscular Atrophy ◽

Muscular Atrophy ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Type 3

T136. Safety and Efficacy of Intravenous Ganaxolone in Severe Postpartum Depression: Results From a Double-Blind, Placebo-Controlled Phase 2 Study

Biological Psychiatry ◽

10.1016/j.biopsych.2019.03.459 ◽

2019 ◽

Vol 85 (10) ◽

pp. S181-S182

Author(s):

Rolando Gutierrez-Esteinou ◽

Bassem Maximos ◽

Robert Riesenberg ◽

Kimball A. Johnson ◽

Alex Aimetti ◽

...

Keyword(s):

Postpartum Depression ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

Pain ◽

10.1016/j.pain.2004.05.001 ◽

2004 ◽

Vol 110 (3) ◽

pp. 628-638 ◽

Cited By ~ 462

Author(s):

Julio Rosenstock ◽

Michael Tuchman ◽

Linda LaMoreaux ◽

Uma Sharma

Keyword(s):

Peripheral Neuropathy ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

A randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of TRPA1, in patients with painful diabetic peripheral neuropathy

Pain ◽

10.1097/j.pain.0000000000002470 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Sunil M. Jain ◽

R. Balamurugan ◽

Monika Tandon ◽

Neelufar Mozaffarian ◽

Girish Gudi ◽

...

Keyword(s):

Peripheral Neuropathy ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial

BMC Neurology ◽

10.1186/1471-2377-8-33 ◽

2008 ◽

Vol 8 (1) ◽

Cited By ~ 117

Author(s):

Joseph C Arezzo ◽

Julio Rosenstock ◽

Linda LaMoreaux ◽

Lynne Pauer

Keyword(s):

Peripheral Neuropathy ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study

Journal of Pain ◽

10.1016/j.jpain.2016.09.008 ◽

2017 ◽

Vol 18 (1) ◽

pp. 42-53 ◽

Cited By ~ 48

Author(s):

David M. Simpson ◽

Jessica Robinson-Papp ◽

Joanna Van ◽

Malcolm Stoker ◽

Hélène Jacobs ◽

...

Keyword(s):

Peripheral Neuropathy ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Soluble Guanylate Cyclase Stimulator

Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

American Heart Journal ◽

10.1016/j.ahj.2020.01.009 ◽

2020 ◽

Vol 222 ◽

pp. 183-190 ◽

Cited By ~ 5

Author(s):

James E. Udelson ◽

Gregory D. Lewis ◽

Sanjiv J. Shah ◽

Michael R. Zile ◽

Margaret M. Redfield ◽

...

Keyword(s):

Heart Failure ◽

Soluble Guanylate Cyclase ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Patients With Heart Failure ◽

SAT0089 SAFETY AND EFFICACY OF LY3337641, A BRUTON’S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY

10.1136/annrheumdis-2019-eular.2672 ◽

2019 ◽

Cited By ~ 1

Author(s):

Mark C. Genovese ◽

Alberto Spindler ◽

Akira Sagawa ◽

Won Park ◽

Anna Dudek ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Phase 2 ◽

Double Blind ◽

Bruton's Tyrosine Kinase ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE‐TPA): A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study

Annals of Neurology ◽

10.1002/ana.25644 ◽

2019 ◽

Vol 87 (2) ◽

pp. 233-245 ◽

Cited By ~ 4

Author(s):

Jong S. Kim ◽

Kyung Bok Lee ◽

Jong‐Ho Park ◽

Sang Min Sung ◽

Kyungmi Oh ◽

...

Keyword(s):

Ischemic Stroke ◽

Acute Ischemic Stroke ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793503497 ◽

2015 ◽

Author(s):

Brendan J Canning

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽